
| Disease Domain | Count | 
|---|---|
| Neoplasms | 6 | 
| Infectious Diseases | 1 | 
| Top 5 Drug Type | Count | 
|---|---|
| Small molecule drug | 5 | 
| Chemical drugs | 2 | 
| Mesenchymal stem cell therapy | 1 | 
Target  | 
Mechanism HIF-1α inhibitors  | 
Active Org.  | 
Originator Org.  | 
Active Indication  | 
Inactive Indication-  | 
Drug Highest PhasePreclinical  | 
First Approval Ctry. / Loc.-  | 
First Approval Date-  | 
Target  | 
Mechanism σ2 receptor antagonists  | 
Active Org.  | 
Originator Org.  | 
Active Indication  | 
Inactive Indication-  | 
Drug Highest PhasePreclinical  | 
First Approval Ctry. / Loc.-  | 
First Approval Date-  | 
Target-  | 
Mechanism-  | 
Active Org.  | 
Originator Org.  | 
Active Indication  | 
Inactive Indication-  | 
Drug Highest PhasePreclinical  | 
First Approval Ctry. / Loc.-  | 
First Approval Date-  | 
Start Date18 Jul 2024  | 
Sponsor / Collaborator  | 
Start Date01 May 2024  | 
Sponsor / Collaborator  [+21]   | 
Start Date23 Feb 2024  | 
Sponsor / Collaborator  | 

| Drug(Targets) | Indications | Global Highest Phase | 
|---|---|---|
Mn2O3-CMC-LA HNMs  | Mouth Neoplasms More  | Preclinical  | 
Dimethyl α-ketoglutarate  (  MMPs ) | Wrinkling of skin More  | Preclinical  | 
LW-1564  (  HIF-1α ) | Neoplasms More  | Preclinical  | 
Dehydroeburicoic acid  (  GSK-3β ) | Neoplasms More  | Preclinical  | 
FPR2 agonists-PDMSC(Dongguk University)  (  FPR2 ) | Fibrosis, Liver More  | Preclinical  | 





